vitronectin antagonists (BMS)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namevitronectin antagonists (BMS)
Drug Alias Namevitronectin antagonists (DuPont)alpha-v beta-3 antagonists (DuPont)alpha-v beta-3 antagonists (BMS)RP-627SU-055 +[10] 
ClassificationSmall molecules
Mechanisms of ActionMetastasis inhibitorsIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsCoronary RestenosisDiabetic RetinopathyOsteoporosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Pharma Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Pharma CompanyBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsCoronary RestenosisDiabetic RetinopathyOsteoporosis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A